Table 1.
Study design, anti-viral regime, and steroid regime in studies on the management of CMV endotheliitis
| Study | Study location | Study design | No. of eyes (patients) | Anti-viral regime | Steroid regime | Mean duration of anti-viral treatmenta |
|---|---|---|---|---|---|---|
| Chee [48] | Singapore | retrospective interventional case series | 12 (10) |
5 patients • 6-week of intravenous ganciclovir 5 mg/kg twice daily • followed by 6 weeks of oral ganciclovir 1 g thrice daily 5 patients • 6 weeks of oral valganciclovir 900 mg twice daily • followed 6-week of oral ganciclovir 900 mg daily |
topical prednisolone acetate 1% twice daily, tapered off over 3 months | 12 weeks |
| Chiang [49] | Taiwan, China | case report | 1 (1) | • oral valganciclovir 900 mg twice daily | 1-week of topical prednisolone 1% 4 times a day for 1 week | 4 months |
| Choi [50] | South Korea | case report | 1 (1) |
• 2 intravitreal ganciclovir injections (unspecific time interval between injections) • topical ganciclovir 0.15% every 2 h |
topical prednisolone acetate 1% 4–6 times daily | N/A |
| Fan [51] | Taiwan, China | retrospective interventional case series | 10 (9) | • topical ganciclovir 0.5% every 2 h for 1 month, then tapered to 4 times per daily | topical prednisolone acetate 1% twice daily, then tapered to once or twice daily | 48 months |
| Hwang [52] | Taiwan, China | case report | 1 (1) | • oral valganciclovir (details N/A) | topical prednisolone acetate 1% 4 times a day | 2 months |
| Hwang [53] | Taiwan, China | retrospective interventional case series | 13 (13) | • topical ganciclovir 2% every 2 h for 2 weeks, then tapered to 4 times a day | topical prednisolone acetate 1% 4 times a day for 2 weeks, then tapered to twice daily | 24.5 months |
| Kam [54] | Hong Kong, China | retrospective interventional case series | 17 (16) |
13 patients • oral valganciclovir 900 mg twice daily and topical ganciclovir ointment 3 patients • topical ganciclovir ointment |
prednisolone acetate 1% ophthalmic suspension | 12.5 months |
| Koizumi [55] | Japan | retrospective, consecutive, multicenter case series. | 8 (8) | • topical ganciclovir 0.15% 6 times per day | topical 0.1% fluorometholone eye drops 4 times daily | 12 weeks |
| Pavan-Langston [56] | USA | case report | 1 (1) | • topical ganciclovir 0.15% every 2 h | topical prednisolone 1% once daily | 4.5 months |
| Wong [57] | Hong Kong, China | retrospective interventional case series | 13 (11) |
• 2-week loading dose of oral valganciclovir 900 mg twice daily • followed by 450 mg twice daily as maintenance |
topical prednisolone acetate 1, 0.5% loteprednol etabonate eye drops, or 1% dexamethasone | ranging from 4 to 38 weeks |
| Yamauchi [58] | Japan | case report | 1 (1) | • 5 weeks oral valganciclovir 1800 mg/dayfollowed by 900 mg/day as maintenance | topical dexamethasone 0.1% 4 times a day | 3 months |
| Yu [59] | China | retrospective interventional case series | 16 (15) |
• oral ganciclovir 1000 mg/60 kg 3 times daily for 4 weeks • followed by 500 mg/60 kg 3 times daily for 8 weeks • multiple intravitreal ganciclovir injections (mean 3.47 injections) • topical ganciclovir 0.15% gel 4 times per day |
topical prednisolone 0.1% 4 times daily with gradual tapering | N/A |
aincludes induction and maintenance period
N/A = not available